col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Portland Press: Clinical Science
  original article Date Title Authors   All Authors
1 [GO] 2021―Dec―08 Erythrocytes increase endogenous sphingosine 1-phosphate (S1P) levels as an adaptive response to SARS-CoV-2 infection Martin Sebastian Winkler, Ralf A Claus, Mareike Schilder, Stefan Pöhlmann, Sina Coldewey, Julian Grundmann, et al. (+6)
2 [GO] 2021―Nov―22 The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147-receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease Elisa Avolio, Michele Carrabba, Rachel Milligan, Maia Kavanagh Williamson, Antonio Beltrami, Kapil Gupta, et al. (+11)
3 [GO] 2021―Aug―02 Role of ACE2 in pregnancy and potential implications for COVID-19 susceptibility Nayara Azinheira Nobrega Cruz, Danielle Stoll, Dulce Elena Casarini, Mariane Bertagnolli
4 [GO] 2021―Apr―21 Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat? Fedor Simko, Tomas Baka
5 [GO] 2021―Feb―06 ACE2 and energy metabolism: the connection between COVID-19 and chronic metabolic disorders Xi Cao, Li-Ni Song, Jin-Kui Yang
6 [GO] 2021―Jan―29 ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease Jithin Kuriakose, Augusto C. Montezano, Rhian M. Touyz
7 [GO] 2021―Jan―23 Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19 Maria A Pedrosa, Rita Valenzuela, Pablo Garrido, Carmen M Labandeira, Gemma Navarro, Rafael Franco, et al. (+2)
8 [GO] 2021―Jan―07 Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases Ravindra K. Sharma, Jing Li, Suraj Krishnan, Elaine M. Richards, Mohan K. Raizada, Rajesh Mohandas
9 [GO] 2020―Dec―11 ACE2, a multifunctional protein - from cardiovascular regulation to COVID-19 Michael Bader, Anthony J. Turner, Natalia Alenina
10 [GO] 2020―Dec―09 ACE2: from protection of liver disease to propagation of COVID-19 Fiona J. Warner, Harinda Rajapaksha, Nicholas Shackel, Chandana B. Herath
11 [GO] 2020―Dec―03 Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists U. Muscha Steckelings, Colin Sumners
12 [GO] 2020―Nov―25 ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19 Koichi Yamamoto, Hikari Takeshita, Hiromi Rakugi
13 [GO] 2020―Nov―04 ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV Lizelle Lubbe, Gyles E. Cozier, Delia Oosthuizen, K. Ravi Acharya, Edward D. Sturrock
14 [GO] 2020―Nov―02 ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery Enrique Lores, Jan Wysocki, Daniel Batlle
15 [GO] 2020―Oct―16 Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease Carlos M. Ferrario, Sarfaraz Ahmad, Leanne Groban
16 [GO] 2020―Sep―29 Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19 Nigel M. Hooper, Daniel W. Lambert, Anthony J. Turner
17 [GO] 2020―Sep―09 Correction: Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission
18 [GO] 2020―Sep―01 Using serpins cysteine protease cross-specificity to possibly trap SARS-CoV-2 Mpro with reactive center loop chimera Mohamad Aman Jairajpuri, Shoyab Ansari
19 [GO] 2020―Aug―21 Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission Daniella S. Battagello, Guilherme Dragunas, Marianne O. Klein, Ana L.P. Ayub, Fernando J. Velloso, Ricardo G. Correa
20 [GO] 2020―Aug―04 Suppressed anti-inflammatory heat shock response in high-risk COVID-19 patients: lessons from basic research (inclusive bats), light on conceivable therapies Thiago Gomes Heck, Mirna Stela Ludwig, Matias Nunes Frizzo, Alberto Antonio Rasia-Filho, Paulo Ivo Homem de Bittencourt
21 [GO] 2020―Jun―16 Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy Jameel M. Inal
22 [GO] 2020―Jun―16 SARS-CoV2 may evade innate immune response, causing uncontrolled neutrophil extracellular traps formation and multi-organ failure Alain R. Thierry, Benoit Roch
23 [GO] 2020―Jun―08 Covid-19: the renin-angiotensin system imbalance hypothesis Katharina Lanza, Lucas G. Perez, Larissa B. Costa, Thiago M. Cordeiro, Vitria A. Palmeira, Victor T. Ribeiro, Ana Cristina Simões e Silva
24 [GO] 2020―May―22 Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs Sayeed ur Rehman, Mohammad Tabish
25 [GO] 2020―Apr―07 ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19 Rhian M. Touyz, Hongliang Li, Christian Delles
26 [GO] 2020―Mar―13 Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Daniel Batlle, Jan Wysocki, Karla Satchell

[de][en]

Last change 2022―Jan―20 20:43:25 UTC

© Daten-Quadrat 2022       Done in 0.004 sec